Menopause

• Exogenous postmenopausal hormone use was associated with increased risk of CHIP among women in the UK Biobank who experienced menopause later in life.
• Among women in the UK Biobank, in an exploratory model adjusted for age, the first 10 principal components of ancestry, and smoking status, premature menopause was associated with 3-fold risk for myeloid dysplasia and neoplasia (hazard ratio [HR], 2.98; P = 0.04).
• Cardiovascular disease is the leading cause of death among women in the United States and globally, 1 and cardiovascular risk increases substantially after menopause.
• A potential first-in-class treatment for menopausal symptoms came to Bayer through its $425 million upfront acquisition of KaNDy Therapeutics last year, and it's expected to enter phase 3 trial in 2021.
• The menopause market is predicted to reach $5.28 billion by 2023.
• Kandy's drug NT-814 is expected to start a final-stage clinical trial next year and could generate peak sales of 1 billion euros ($1.17 billion) globally.
• The number of new fractures in the EU was about 3.5 million, comprising approximately 620,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures by 2025.
• A small biotech in England has a blockbuster drug for menopause patients, and now plans to spend at least $425 million dollars to acquire it.
• The global menopause treatment market is projected to grow 4.2% from 2017 to 2023.
• Forbes has identified menopause as the next big opportunity in femtech, given the growing market; by 2025, women experience menopause will make up 12% of the entire global population.
• Up to 80% of women may experience symptoms during menopause and it is estimated that in 2030 the at risk groups of pre and post- menopausal women will reach 1.2 billion globally.
• The women of today can expect to spend more years of their longer lifespan post-menopause than they spent in their reproductive era.
• The global market for treatments for menopause is expected to reach $3.3 billion in value by 2023.
• The recent favourable trends in ovarian cancer mortality in North America and Europe can be partly or largely attributed to the long-term protection of OC on ovarian cancer risk and recent declines in menopausal hormonal therapy use.
• Some EU citizens are at a risk of copper deficiency.
• Technavio's analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.
• A new paper suggests a link between polybrominated diphenyl ethers (PBDEs) and increased risk of thyroid problems in post-menopausal women in a nationally representative sample of women in the U.S.
• Regular physical activity reduces the risk of breast and colon cancer, dementia, heart attacks.
• Hormones that women already take for contraception, hormone replacement therapy, infertility treatments or other medical uses could play a powerful role in reducing infection.
• Fatter women produce more oestrogen and have a higher background risk of breast cancer than thinner women.
• Aubrey de Grey has claimed rapid progress in stem cell and regenerative therapies may mean the current limits on when women are able to conceive and give birth could vanish.

Last updated: 07 March 2021